. 2022 Jan 10;20(3):395–404. doi: 10.1007/s40258-021-00711-y

Table 4.

The mean ICERs without herd immunity and the average percentage reduction in ICERs with the inclusion of herd immunity

	ICER	Without HI effects	Actual ICER reduction with HI	Percentage reduction in ICER with HI (mean)^a (%)
All studies^b (mean)	$/QALY (n = 14)	$55,552	$41,074	28
All studies^b (mean)	$/DALY (n = 23)	$11,211	$6,470	61
Pneumococcal Disease^b (mean)	$/QALY (n = 11)	$61,789	$48,056	31
Pneumococcal Disease^b (mean)	$/DALY (n = 4)	$2,681	$1,728	49

ICER incremental cost-effectiveness ratio, HI herd immunity, QALY quality-adjusted life-year, DALY disability-adjusted life-year

^aThe average of the percentage reduction of each ICER pair. It does not equal to the actual ICER reduction with HI over the ICER without HI effects

^bCost-saving results are not included